Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05125822

Adaptive Mechanisms Responsible for Weight Change in Youth With Obesity

In this study, doctors want to find out more about why people who lose weight often regain the weight that they have lost once they resume a regular diet and whether hormones might play a role in weight regain. The study is divided into two parts, called the meal replacement period and the follow-up period. The meal replacement period will consist of drinking a shake for breakfast and lunch and eating a frozen meal for dinner that is calorie controlled. Individuals will also be asked to eat two servings of fruit and three servings of vegetables each day. The study will provide the shakes and the frozen entrees, participants are asked to supply the fruits and vegetables.

Participation in this study will last for up to 35 weeks. There will be 10 in-person visits and 13 visits by phone or over Zoom over the 35 weeks.

Recruiting

Interested in participating?

Request Info

Key information

Age range

11 year–15 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ann & Robert H Lurie Children's Hospital of Chicago

Chicago, Illinois, 60611, United States

Location status: Recruiting

Location contact

Justin R Ryder

CONTACT

[email protected]

3148826838

Justin Ryder, PhD

PRINCIPAL_INVESTIGATOR

About this study

Individuals who are found to be eligible to participate will have two study interventions: An 8-week meal replacement therapy period in which they are asked to reduce their BMI by >5%. Participants will be asked to strictly follow the individually-prescribed eating regimen which will include meal replacement shakes and/or frozen meals to be used for breakfast and lunch. For dinner, the study will provide pre-packaged frozen entrée meals to be consumed with two servings of fruit and three servings of vegetables per day. Meal replacement compliance will be assessed by requiring participants to maintain a dietary log throughout the study. The percentage of days for which the protocol was followed (no additional calories consumed) will serve as the primary metric of compliance.

Participants will also receive a standardized lifestyle/behavioral modification counseling every 2 weeks throughout the entire study, which will be delivered at each in-person study visit and via virtual platform of phone when there is no in-person study visit scheduled. The lifestyle curriculum will incorporate evidence-based behavior change principles including dietary modification, energy expenditure modification, behavior modification and family involvement and support. To ensure fidelity and adherence to the delivery protocol, a manual will be developed for each session that trained staff will follow when administering the curriculum.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 11 to less than 16 years old
  • BMI > 30 kg/m^2 or 95th BMI percentile
  • Tanner stage 2, 3, or 4

Exclusion criteria

  • Tanner stage 1 and 5
  • Prior bariatric surgery
  • Current or recent (< 3 months prior to enrollment) use of anti-obesity medication(s) defined as orlistat, metformin, phentermine, topiramate, combination phentermine/topiramate, liraglutide, and/or combination naltrexone/bupropion (monotherapy use of naltrexone or bupropion is not an exclusion)
  • Monogenic and hypothalamic obesity
  • Polycystic ovary syndrome (diagnosed by a physician)
  • Pregnancy or planned pregnancy
  • Current use of supplemental hormones
  • Individuals with a diagnosed eating disorder of anorexia nervosa, bulimia or binge eating disorder
  • Type 1 or 2 diabetes
  • Treatment with growth hormones
  • Thyroid disease/problem
  • Has had cancer in the last 10 years

Treatment and study plan

Meal replacement and lifestyle modification

Other

Meal replacement and lifestyle modification

Primary outcomes

  1. Change in fat mass regain after initial weight loss with meal replacement therapy (MRT)

    Time frame: 17 weeks.

    We hypothesize that the greater the initial weight loss with MRT the greater the fat mass regain at 26 weeks.

  2. Change in ghrelin

    Time frame: 17 weeks.

    We hypothesize that after the initial weight loss with MRT that we will see an increase in the level of the appetite regulating hormone ghrelin.

  3. Change in gastric inhibitory polypeptide

    Time frame: 17 weeks

    We hypothesize that after the initial weight loss with MRT that we will see an increase in the level of the appetite regulating hormone gastric inhibitory polypeptide.

Study contacts

Contact information is provided by the study sponsor or research team.

Justin Ryder, PhD

CONTACT

[email protected]

3148826838

Sponsors and collaborators

Lead sponsor

Ann & Robert H Lurie Children's Hospital of Chicago

Other

Registry information

Acronym: ADMIRE

Important dates

Study start
2023
Primary completion
2028
Study completion
2028
First posted
Nov 18, 2021
Registry last updated
Jun 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.